Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock Forecast & Price Target
Reviva Pharmaceuticals Holdings Inc. · NASDAQ
$0.46-0.02 (-3.87%)
15-min delayed · Aug 25, 3:30 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Reviva Pharmaceuticals Holdings Inc, 5 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $7.00 (about 3.5x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $3.75 sits 715% above the current $0.46. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy571%
Hold229%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Reviva Pharmaceuticals Holdings Inc.
As of Aug, 5 of 7 firms rate RVPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RVPH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.16 – $-0.16 · 1 analysts · -97% YoY
Next period, 1 analysts expect Reviva Pharmaceuticals Holdings Inc. to earn $-0.16 a share (range $-0.16 – $-0.16), versus $-5.19 a year earlier. Full-year consensus is $-0.85, growing to $-0.85 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Reviva Pharmaceuticals Holdings Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RVPH.
#1
Keay Nakae
Chardan Capital · Rank #85
Buy
$2.00+334.8% to target
Overall win rate
43%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #294
Buy
$4.00+769.6% to target
Overall win rate
37%
+ Follow
#3
Bruce Jackson
Benchmark · Rank #366
Buy
$7.00+1421.7% to target
Overall win rate
36%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton RVPH
Overall win rate
22%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #417
Hold
No targeton RVPH
Overall win rate
33%
+ Follow
RVPH stock forecast FAQ
What is RVPH's average 12-month price target?+
The 3 analysts with a live target average $3.75 for Reviva Pharmaceuticals Holdings Inc. over the next 12 months, ranging from a $7.00 high to a $2.00 low.
Is RVPH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 5 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RVPH?+
The Street-high target is $7.00 (Benchmark), and the Street-low is $2.00 (Chardan Capital). The average of all 3 active targets is $3.75.
How many Wall Street analysts cover RVPH?+
7 analysts have an active rating on Reviva Pharmaceuticals Holdings Inc., and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering RVPH?+
Among analysts who currently cover RVPH, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #85). Their current call is Buy with a $2.00 target.
What is Reviva Pharmaceuticals Holdings Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.16 – $-0.16) across 1 analysts. Full-year EPS is projected at $-0.85, rising to $-0.85 the following year.
How much revenue is Reviva Pharmaceuticals Holdings Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading RVPH lately?+
As of Aug, 5 of 7 firms rate RVPH a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RVPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
